We are live on ! Find out more
NXTC icon

NextCure
NXTC

Fund managers haven’t disclosed any holdings of NXTC yet.

NXTC Hedge Fund Activity: Q1 2026 in Review

26 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2026, worth a combined $23M — down 15% from $26.9M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NXTC positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $1.72M. The largest seller was Exome Asset Management, cutting an estimated $605K.

  • 26 institutional investors held NextCure (NXTC) as of Q1 2026, up from 24 in Q4 2025.
  • Funds reported $23M of NextCure stock for Q1 2026, down 15% quarter-over-quarter.
  • 7 funds opened new NextCure positions in Q1 2026 and 4 closed out, a net change of +3 holders.
  • The largest NextCure buyer in Q1 2026 was Opaleye Management, an estimated $1.72M added.
  • The largest NextCure seller in Q1 2026 was Exome Asset Management, an estimated $605K sold.

Based on aggregated 13F filings for Q1 2026.